Hsbc Holdings PLC Increases Stock Position in Labcorp Holdings Inc. $LH

Hsbc Holdings PLC raised its position in Labcorp Holdings Inc. (NYSE:LH) by 33.8% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 189,502 shares of the medical research company’s stock after buying an additional 47,850 shares during the period. Hsbc Holdings PLC owned 0.23% of Labcorp worth $47,608,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Thurston Springer Miller Herd & Titak Inc. bought a new stake in Labcorp in the fourth quarter worth about $26,000. Hilton Head Capital Partners LLC bought a new stake in Labcorp in the 4th quarter valued at about $27,000. JPL Wealth Management LLC purchased a new stake in Labcorp during the third quarter valued at about $28,000. Eagle Bay Advisors LLC bought a new position in Labcorp during the fourth quarter worth about $29,000. Finally, DV Equities LLC bought a new position in Labcorp during the fourth quarter worth about $29,000. 95.94% of the stock is currently owned by institutional investors.

Labcorp Price Performance

Labcorp stock opened at $286.69 on Monday. The business has a 50-day simple moving average of $262.24 and a 200 day simple moving average of $266.27. The company has a quick ratio of 1.54, a current ratio of 1.73 and a debt-to-equity ratio of 0.68. The stock has a market cap of $23.51 billion, a price-to-earnings ratio of 25.39, a PEG ratio of 2.01 and a beta of 0.89. Labcorp Holdings Inc. has a 52 week low of $241.81 and a 52 week high of $293.72.

Labcorp (NYSE:LH) last announced its quarterly earnings data on Thursday, April 30th. The medical research company reported $4.25 earnings per share for the quarter, topping analysts’ consensus estimates of $4.09 by $0.16. Labcorp had a net margin of 6.66% and a return on equity of 16.29%. The firm had revenue of $3.54 billion during the quarter, compared to analyst estimates of $3.51 billion. During the same period in the previous year, the business posted $3.84 EPS. The business’s quarterly revenue was up 5.8% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. On average, research analysts forecast that Labcorp Holdings Inc. will post 18 earnings per share for the current fiscal year.

Labcorp Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, June 11th. Stockholders of record on Friday, May 29th were paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date was Friday, May 29th. Labcorp’s dividend payout ratio (DPR) is presently 25.51%.

Wall Street Analyst Weigh In

LH has been the topic of several research reports. Wall Street Zen lowered shares of Labcorp from a “buy” rating to a “hold” rating in a research report on Saturday, June 13th. Evercore reiterated an “outperform” rating and issued a $300.00 price objective on shares of Labcorp in a research note on Wednesday, April 8th. Robert W. Baird set a $334.00 target price on shares of Labcorp in a report on Friday, May 1st. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of Labcorp in a research report on Friday, May 8th. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $308.00.

Insider Activity

In other news, CEO Adam H. Schechter sold 5,903 shares of Labcorp stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $254.50, for a total value of $1,502,313.50. Following the completion of the sale, the chief executive officer directly owned 107,234 shares in the company, valued at $27,291,053. The trade was a 5.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Kathryn W. Kyle sold 762 shares of the company’s stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $263.89, for a total transaction of $201,084.18. Following the sale, the executive vice president directly owned 3,813 shares of the company’s stock, valued at $1,006,212.57. The trade was a 16.66% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.84% of the company’s stock.

About Labcorp

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.